Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Smith

Physician Assistant Hoover, AL Physician Assistant

NPI 1255876686 CMS profile 11165228

2279 Valleydale Rd Ste 100, Hoover, AL 35244

Open in the dashboard

General payments

$11,096

451 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Smith of Hoover, AL is reported in the CMS Open Payments database as having received $11,096 across 451 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,495 67
2024 General $5,052 163
2023 General $2,301 112
2022 General $1,601 85
2021 General $648 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Smith
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Elizabeth Smith were reported at $1,495. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Elizabeth Smith Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $648 $132 $37–$438 $132
2022 $1,601 $155 $48–$522 $149
2023 $2,301 $167 $52–$557 $160
2024 $5,052 $178 $55–$600 $164
2025 $1,495 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,317 151 payments
  2. Novartis Pharmaceuticals Corporation $1,127 50 payments
  3. Sun Pharmaceutical Industries Inc. $684 28 payments
  4. Genzyme Corporation $605 22 payments
  5. Regeneron Healthcare Solutions, Inc. $548 15 payments
  6. Janssen Biotech, Inc. $475 25 payments
  7. LEO Pharma Inc. $425 22 payments
  8. E.R. Squibb & Sons, L.L.C. $409 24 payments
  9. Pfizer Inc. $388 21 payments
  10. Lilly USA, LLC $314 13 payments
  11. Other $1,804 80 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,788 444 payments
  2. Travel and Lodging $997 3 payments
  3. Education $312 4 payments
Products named General payments · program years 2021–2025
  1. BOTOX $1,032 60 payments
  2. DUPIXENT Immunology $785 27 payments
  3. RINVOQ $691 24 payments
  4. SKYRIZI $583 32 payments
  5. COSENTYX $580 23 payments
  6. DUPIXENT Inflammation And Immunology $533 14 payments
  7. TREMFYA $410 21 payments
  8. SOTYKTU $409 24 payments
  9. ADBRY $408 21 payments
  10. VTAMA $353 9 payments
  11. Other $3,917 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$26,217

Medicare's payments for the services billed

Medicare patients

153

Average age 74

Services billed

792

109 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 44%
Diabetes 25%
Depression 20%
Osteoporosis 20%
Chronic kidney disease 19%
Ischemic heart disease 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $182
  • Regeneron Healthcare Solutions, Inc. $154
$336 — —
RINVOQ
  • AbbVie, Inc. $318
$318 — —
BOTOX
  • AbbVie, Inc. $294
$294 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $282
$282 — —
SKYRIZI
  • AbbVie, Inc. $281
$281 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record